219 related articles for article (PubMed ID: 35236742)
1. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies.
Glez-Vaz J; Azpilikueta A; Olivera I; Cirella A; Teijeira A; Ochoa MC; Alvarez M; Eguren-Santamaria I; Luri-Rey C; Rodriguez-Ruiz ME; Nie X; Chen L; Guedan S; Sanamed MF; Perez Gracia JL; Melero I
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236742
[TBL] [Abstract][Full Text] [Related]
2. New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis.
Etxeberria I; Glez-Vaz J; Teijeira Á; Melero I
ESMO Open; 2020 Jul; 4(Suppl 3):e000733. PubMed ID: 32611557
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced soluble CD137 in malignant cells blocks CD137L-costimulation as an immune escape mechanism.
Labiano S; Palazón A; Bolaños E; Azpilikueta A; Sánchez-Paulete AR; Morales-Kastresana A; Quetglas JI; Perez-Gracia JL; Gúrpide A; Rodriguez-Ruiz M; Aznar MA; Jure-Kunkel M; Berraondo P; Melero I
Oncoimmunology; 2016; 5(1):e1062967. PubMed ID: 26942078
[TBL] [Abstract][Full Text] [Related]
4. CD137 Agonists Targeting CD137-Mediated Negative Regulation Show Enhanced Antitumor Efficacy in Lung Cancer.
Yi L; Jin X; Wang J; Yan Z; Cheng X; Wen T; Yang B; Wang X; Che N; Liu Z; Zhang H
Front Immunol; 2022; 13():771809. PubMed ID: 35197968
[TBL] [Abstract][Full Text] [Related]
5. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary.
Melero I; Sanmamed MF; Glez-Vaz J; Luri-Rey C; Wang J; Chen L
Cancer Discov; 2023 Mar; 13(3):552-569. PubMed ID: 36576322
[TBL] [Abstract][Full Text] [Related]
6. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
7. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.
Srivastava RM; Trivedi S; Concha-Benavente F; Gibson SP; Reeder C; Ferrone S; Ferris RL
Clin Cancer Res; 2017 Feb; 23(3):707-716. PubMed ID: 27496866
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients.
Räth U; Mester P; Schwarz H; Schmid S; Müller M; Buechler C; Pavel V
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139346
[TBL] [Abstract][Full Text] [Related]
9. M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation.
Xu C; Zhou X; Webb L; Yalavarthi S; Zheng W; Saha S; Schweickhardt R; Soloviev M; Jenkins MH; Brandstetter S; Belousova N; Alimzhanov M; Rabinovich B; Deshpande AM; Brewis N; Helming L
Cancer Immunol Res; 2024 Feb; 12(2):195-213. PubMed ID: 38091375
[TBL] [Abstract][Full Text] [Related]
10. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
[TBL] [Abstract][Full Text] [Related]
11. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.
Kachapati K; Bednar KJ; Adams DE; Wu Y; Mittler RS; Jordan MB; Hinerman JM; Herr AB; Ridgway WM
J Autoimmun; 2013 Dec; 47():94-103. PubMed ID: 24145149
[TBL] [Abstract][Full Text] [Related]
12. BT7480, a novel fully synthetic
Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
[TBL] [Abstract][Full Text] [Related]
13. CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8
Aznar MA; Labiano S; Diaz-Lagares A; Molina C; Garasa S; Azpilikueta A; Etxeberria I; Sanchez-Paulete AR; Korman AJ; Esteller M; Sandoval J; Melero I
Cancer Immunol Res; 2018 Jan; 6(1):69-78. PubMed ID: 29133290
[TBL] [Abstract][Full Text] [Related]
14. Characterisation of soluble murine CD137 and its association with systemic lupus.
Shao Z; Sun F; Koh DR; Schwarz H
Mol Immunol; 2008 Sep; 45(15):3990-9. PubMed ID: 18640726
[TBL] [Abstract][Full Text] [Related]
15. Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity.
Ceccarelli F; Natalucci F; Di Filippo A; Olivieri G; Napoletano C; Rughetti A; Nuti M; Zizzari IG; Conti F
J Immunol Res; 2023; 2023():2344239. PubMed ID: 37114204
[TBL] [Abstract][Full Text] [Related]
16. Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG; Di Filippo A; Botticelli A; Strigari L; Pernazza A; Rullo E; Pignataro MG; Ugolini A; Scirocchi F; Di Pietro FR; Rossi E; Gelibter A; Schinzari G; D'Amati G; Rughetti A; Marchetti P; Nuti M; Napoletano C
Clin Cancer Res; 2022 Mar; 28(5):1027-1037. PubMed ID: 34980602
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy.
Liu G; Luo P
Front Immunol; 2023; 14():1208788. PubMed ID: 37334375
[TBL] [Abstract][Full Text] [Related]
18. Expression of soluble CD137 correlates with activation-induced cell death of lymphocytes.
Michel J; Schwarz H
Cytokine; 2000 Jun; 12(6):742-6. PubMed ID: 10843756
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
20. Enhanced levels of soluble and membrane-bound CD137 levels in patients with acute coronary syndromes.
Dongming L; Zuxun L; Liangjie X; Biao W; Ping Y
Clin Chim Acta; 2010 Mar; 411(5-6):406-10. PubMed ID: 20026323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
